Medtech and pharma companies operating in Australia have just over three weeks to comment on draft Australian guidance on how to choose the most appropriate regulatory pathway for products that do not clearly fit within the existing definitions for medicines, biologicals or medical devices.
The new guidance, which has been drafted by the Therapeutic Goods Administration, is intended to replace the existing guideline on “device-medicine boundary products,” which dates from November 2005 and...